ABSTRACT
We report a case of primary pulmonary hypertension who benefited from oral Sildenafil therapy. Sildenafil, a selective phosphodiesterase type 5 inhibitor which acts as a pulmonary vasodilator, led to an improved clinical condition, exercise performance and haemodynamic parameters which were maintained at 6 months of follow up. Larger trials are warranted.
Subject(s)
Administration, Oral , Adolescent , Dose-Response Relationship, Drug , Drug Administration Schedule , Echocardiography, Doppler , Electrocardiography/methods , Female , Follow-Up Studies , Hemodynamics/physiology , Humans , Hypertension, Pulmonary/diagnosis , India , Piperazines/therapeutic use , Positron-Emission Tomography/methods , Purines , Respiratory Function Tests , Severity of Illness Index , Sulfones , Treatment Outcome , Vasodilator Agents/administration & dosageABSTRACT
Upper extremity deep vein thrombosis (UEDVT) is a rare thrombotic disorder (1-4% or all DVT), but it has a potential for considerable morbidity in the form of pulmonary embolism, persistent upper extremity pain and swelling, superior vena cava syndrome and loss of vascular access. Newer non-invasive methods such as duplex ultrasound and magnetic resonance angiography facilitate early diagnosis. Early catheter directed thrombolysis followed by anticoagulation prevent long-term sequalae.